<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474590</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29099</org_study_id>
    <nct_id>NCT01474590</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne</brief_title>
  <acronym>POWER</acronym>
  <official_title>Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group
      comparison study in subjects with severe acne vulgaris on the face.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements</measure>
    <time_frame>20 weeks</time_frame>
    <description>Overall success is reached when the 2 following criteria are fulfilled :
Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment
Safe treatment: Absence of any listed safety issues</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Epiduo/Tactuo + doxycycline 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotretinoin + vehicle gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo/Tactuo</intervention_name>
    <description>topical to the face, once daily in the evening</description>
    <arm_group_label>Epiduo/Tactuo + doxycycline 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vehicle gel</intervention_name>
    <description>topical to the face, once daily in the evening</description>
    <arm_group_label>Isotretinoin + vehicle gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline 200mg</intervention_name>
    <description>oral, 2 capsules once daily in the morning with aglass of water and with food</description>
    <arm_group_label>Epiduo/Tactuo + doxycycline 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.</description>
    <arm_group_label>Isotretinoin + vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject of any race, aged 12 to 35 years inclusive

          2. Subject weighing between 50 and 110 kg

          3. Subject with severe acne (IGA at least 4), which in the opinion of the investigator is
             appropriate for treatment with oral isotretinoin (severe nodular acne, severe
             inflammatory acne, recalcitrant acne; all unresponsive to conventional first line
             therapies)

          4. Subject with at least 5 nodules on the face

        Exclusion Criteria:

          1. Subject with clinically abnormal results to blood testings performed at screening

          2. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced
             acne, etc.), pyoderma faciale, sinus tracks

          3. Female subject who is pregnant, nursing or planning a pregnancy during the study

          4. Subject with known history of hepatic and/or renal insufficiency, to be confirmed by
             blood testings

          5. Subject with known metabolic or structural bone disease (for 12-17 years old
             population)

          6. Subject with bowel disease and/or with hypervitaminosis A

          7. Subject who presents with treated or untreated depression or has a history of
             depression including a family history of major depression

          8. Subject with a wash-out period from baseline for topical treatment on the face less
             than : Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other
             anti-inflammatory drugs or other acne treatments (2 weeks); Cosmetic procedures (1
             week); Photodynamic therapy and laser therapy for acne (3 months)

          9. Subject with a wash-out period from baseline for systemic treatment less than:
             Corticosteroids, antibiotics (4 weeks),Progesterone for contraception (3 months);
             Spironolactone(3 months); Other acne treatments (6 months);Cyproterone acetate(6
             months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Tan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Windsor Clinical Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Ajax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Barrie</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Markham</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Newmarket</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Oakville</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Oshawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Peterborough</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Quebec city</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Richmond Hill</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Saint-Hyacinthe</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Saint-John's</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Saskatoon</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>St John's</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Sudbury</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Surrey</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Waterloo</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Windsor</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma investigational site</name>
      <address>
        <city>Woodbridge</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2017</results_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Epiduo/Tactuo + Doxycycline 200mg</title>
          <description>Epiduo/Tactuo + doxycycline 200mg: Epiduo gel: topical to the face, once daily in the evening Doxycycline: oral, 2 capsules a day. The capsules should be taken with a glass of water and with food either as a single dose or in two divided doses during the day.</description>
        </group>
        <group group_id="P2">
          <title>Isotretinoin + Vehicle Gel</title>
          <description>Isotretinoin + vehicle gel: Vehicle gel: topical to the face, once daily in the evening Isotretinoin: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epiduo/Tactuo + Doxycycline 200mg</title>
          <description>Epiduo/Tactuo + doxycycline 200mg: Epiduo gel: topical to the face, once daily in the evening Doxycycline: oral, 2 capsules a day. The capsules should be taken with a glass of water and with food either as a single dose or in two divided doses during the day.</description>
        </group>
        <group group_id="B2">
          <title>Isotretinoin + Vehicle Gel</title>
          <description>Isotretinoin + vehicle gel: Vehicle gel: topical to the face, once daily in the evening Isotretinoin: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="5.0"/>
                    <measurement group_id="B2" value="19.3" spread="4.5"/>
                    <measurement group_id="B3" value="19.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IGA</title>
          <description>the global severity assessment is outlined as per below:
Investigator’s Global Assessment (IGA)
score
0. Clear: Residual hyperpigmentation and erythema may be present
Almost Clear A few scattered comedones and a few small papules
Mild Some comedones and some papules and pustules. No nodules present
Moderate Many comedones, papules and pustules. One nodule may be present
Severe Covered with comedones, numerous papules and pustules and few nodules may be present
Very severe Highly inflammatory acne covering the face; with nodules present</description>
          <units>count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>nodule counts</title>
          <units>nodules</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="3.6"/>
                    <measurement group_id="B2" value="7.6" spread="2.5"/>
                    <measurement group_id="B3" value="7.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements</title>
        <description>Overall success is reached when the 2 following criteria are fulfilled :
Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment
Safe treatment: Absence of any listed safety issues</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epiduo/Tactuo + Doxycycline 200mg</title>
            <description>Epiduo/Tactuo + doxycycline 200mg: Epiduo gel: topical to the face, once daily in the evening Doxycycline: oral, 2 capsules a day. The capsules should be taken with a glass of water and with food either as a single dose or in two divided doses during the day.</description>
          </group>
          <group group_id="O2">
            <title>Isotretinoin + Vehicle Gel</title>
            <description>Isotretinoin + vehicle gel: Vehicle gel: topical to the face, once daily in the evening Isotretinoin: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements</title>
          <description>Overall success is reached when the 2 following criteria are fulfilled :
Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment
Safe treatment: Absence of any listed safety issues</description>
          <units>count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Epiduo/Tactuo + Doxycycline 200mg</title>
          <description>Epiduo/Tactuo + doxycycline 200mg: Epiduo gel: topical to the face, once daily in the evening Doxycycline: oral, 2 capsules a day. The capsules should be taken with a glass of water and with food either as a single dose or in two divided doses during the day.</description>
        </group>
        <group group_id="E2">
          <title>Isotretinoin + Vehicle Gel</title>
          <description>Isotretinoin + vehicle gel: Vehicle gel: topical to the face, once daily in the evening Isotretinoin: oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens–Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>lip dry</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="72" subjects_affected="66" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>cheilitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>naospharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>UPTRI (Upper Tract Respiratory Infection)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="133"/>
                <counts group_id="E2" events="56" subjects_affected="43" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>skin irritation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jerry Tan</name_or_title>
      <organization>University of Western Ontario and Windsor Clinical Research Inc., 2224 Walker Rd. Suite 300, Windsor, ON, Canada</organization>
      <email>jerrytan@bellnet.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

